Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
(5 intermediate revisions by the same user not shown)
Line 6: Line 6:
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===
  
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers 2023-03-28]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|<u>CT Atherosclerosis Biomarkers 2023-03-28</u>]]
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19]]
+
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|<u>CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19</u>]]
  
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists
+
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|<u>CT Tumor Volume Change for Advanced Disease 2022-07-21</u>]] - Streamlined Profile including Conformance Checklists
  
*[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]]
+
*[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| <u>MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15</u>]]
  
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver 2022-02-14]]
+
*[[Media:MRE-QIBAProfile-2023-11-07-CLINICALLY-FEASIBLE-maintenance.pdf|''<u>MR Elastography of the Liver, Clinically Feasible Profile: Maintenance draft. November 7, 2023</u>'']]  [[Media:MRE-QIBAProfile-2023-11-07-CLINICALLY-FEASIBLE-maintenance.pdf|''doi:10.1128/QIBA/20231107'']]
  
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid 2022-06-03]]
+
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|<u>MR Elastography of the Liver 2022-02-14</u>]]
  
*[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v114, 2023-08-16, contains updated checklist]]
+
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|<u>PET Amyloid 2022-06-03</u>]]
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]
+
 
 +
*[[Media:QIBA FDG-PET Profile v114.pdf|<u>PET/CT FDG SUV for Response to Cancer Therapy, v114, 2023-08-16</u>, contains updated checklist]]
 +
*[[Media:QIBA FDG-PET Profile v113.pdf|<u>PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18</u>]]
 
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
  
*[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf | US Shear Wave Speed for Liver Fibrosis 2024-01-15]]
+
*[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf| <u>US Shear Wave Speed for Liver Fibrosis 2024-01-15</u>]]
 
::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E 2023-12-28]]
 
::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E 2023-12-28]]
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]]
+
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|<u>US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023</u>]]
  
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
Line 43: Line 45:
 
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
 
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
  
*[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf | US Volume Blood Flow Profile, Consensus version 2024-01-05]]
+
*[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf| US Volume Blood Flow Profile, Consensus version 2024-01-05]]
  
 
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]
 
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]

Revision as of 15:08, 18 April 2024

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.

Tools to aid Biomarker Committees in collating these comments:


QIBA Profiles and Clinical Applications


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also